相关实验视频

Updated: Mar 7, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

微轴流量在不同心脏性休克表型中的使用 - - DanGer休克试验的二次分析

Elric Zweck¹, Rasmus P Beske², Christian Hassager³

¹Department of Cardiology, Pulmonology and Vascular Medicine, University Hospital Düsseldorf, Medical Faculty of the Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Journal of cardiac failure

|March 5, 2026

概括

心脏性休克 (CS) 现型具有不同的结果,非拥挤的CS表现最好,心脏代谢性CS表现最差. 微轴流 (mAFP) 的使用在非拥挤的CS患者中显示出最大的死亡益处.

科学领域:

心脏病学心脏病学
临界护理医学临界护理医学
翻译研究是翻译研究.

背景情况:

在患者数据集中验证了三种不同的心脏性休克 (CS) 现象型 - - 非拥挤性,心脏性和心脏代谢性.
此前,DanGer Shock试验已经确定了微轴流 (mAFP) 在心肌梗塞相关的CS中使用的死亡益处.
本次后期分析调查了这些CS表型在DanGerShock试验人群中的轨迹和结果.

研究的目的:

以追溯的方式将DanGerShock试验中的患者分配给三种预定义的CS表型之一.
在最初的72小时内分析每个CS表型内的临床,实验室和血液动力学轨迹.
评估180天死亡结果,按CS表型分层,并分配到mAFP或标准护理.

主要方法:

患者被追溯分为非拥挤 (41%),心脏 (11%),或心脏代谢 (48%) 的CS表型.
用多个随机森林归算来解决缺少的表型化数据.
评估了180天死亡率和临床参数轨迹,按mAFP或标准护理分配分层.

主要成果:

180天的死亡率在心脏代谢性CS表型中最高 (69%),其次是心脏内CS (47%),在非拥挤的CS中最低 (33%).
临床,代谢和血液动力学轨迹以及治疗反应在CS表型之间存在显著差异.
使用mAFP与非拥挤的CS (OR 0.51 [0.28-0.91],p=0.02) 的死亡率降低有关,而在其他表型中没有显著的益处.

结论:

预定义的CS表型表现出明显的临床结果,心脏代谢性CS与最差的预后相关,非拥挤的CS与最佳相关.
在非拥挤的CS表型中,mAFP的明显死亡益处最为明显.
这些发现表明了表型特定的治疗策略,并保证了未来的验证.

关键词:

发生心脏性休克.这就是Impella Impella.微轴流量是一个微轴流量.肌肉心脏病发作肌肉心脏病发作结果的结果.现象类型现象类型

更多相关视频

The Intra-Aortic Balloon Pump

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

相关概念视频

Cardiopulmonary Resuscitation IV: Pharmacological Management

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Blood Pressure Imbalances and Circulatory Shock

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...